When making treatment decisions, knowledge is power
An advanced cancer diagnosis can change your life. You and your loved ones may feel overwhelmed with questions.
If you don’t know where to start when thinking about treatment options, there’s something you can do. Start With Step One—ask your doctor about the Foundation Medicine testing options, including the FoundationOne®CDx and FoundationOne®Liquid CDx tests.
Foundation Medicine tests use comprehensive genomic profiling, also known as CGP, to find information in your tumor’s DNA that may help your doctor identify a personalized cancer treatment plan that is right for you.
Understanding your tumor’s DNA may inform the treatment options available to you. Learn more in the video.


A personalized advanced cancer treatment plan can give you more control
Scientists and researchers, dedicated to transforming cancer care, have learned more about cancer in the past 20 years than at any other point in history.1
One discovery is the difference that understanding your tumor’s DNA can make when creating a treatment plan. This information, known as genomic information, has led to the development of treatments based on a patient’s cancer DNA, as well as the development of tests that can identify the associated treatment options that may work best based on mutations in a patient’s cancer DNA.
Foundation Medicine tests provide genomic information based on your tumor’s DNA to help you and your doctor create a treatment plan that’s right for you.
A personalized cancer treatment plan matters.
Meet Ed Russ, diagnosed with Stage 4 colon cancer. Watch as he and his wife, Sandy, explain how his test results impacted his treatment plan.*
*Metastatic colorectal cancer (mCRC) is a complex disease, and mCRC patients have a 14% survival rate five years after their diagnosis.2 43% of mCRC patients are matched to an on-label therapy, but a match does not guarantee that the treatment is right for a patient or that a patient will achieve a similar outcome.3 Speak with your doctor for more information.
*Metastatic colorectal cancer (mCRC) is a complex disease, and mCRC patients have a 14% survival rate five years after their diagnosis.2 43% of mCRC patients are matched to an on-label therapy, but a match does not guarantee that the treatment is right for a patient or that a patient will achieve a similar outcome.3 Speak with your doctor for more information.

You are your best advocate.

Ask your doctor about the Foundation Medicine testing options. This guide will help prepare you for the discussion.

Stay connected. Stay informed.

Advanced cancer can come with many unknowns. Foundation Medicine is committed to keeping you and your loved ones informed, educated, and empowered. Sign up to receive email updates from us.

By clicking Sign Up, you agree to our privacy policy and terms of use.
American Cancer Society. https://www.cancer.org/cancer/cancer-basics/history-of-cancer.html
American Cancer Society. Cancer Facts & Figures 2021. Atlanta, Ga: American Cancer Society; 2021.
Data on File.
